Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 24, 2026ESMO OpenOpen Access

First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

VEV. Ekström-RydénACA. CarneiroJYJ. Yachnin

Discussion

Loading...

Member takes

Overview

Phase I study shows safety of ATOR-1015 in advanced solid cancer, suggesting the need for improved antibody design.

Key Points

  • This study aims to evaluate the safety, tolerability, and preliminary efficacy of the bispecific antibody ATOR-1015 in patients with advanced solid malignancies.
  • Conducted a phase I, multicenter trial
  • Administered ATOR-1015 intravenously every second week
  • Applied a modified 3 + 3 dose-escalation design for treatment.
  • Common adverse events included infusion-related reactions in 50% of patients and 39.3% had stable disease.
  • Notable increases in specific T-cell populations and cytokines were observed post-infusion.
  • Most patients developed anti-drug antibodies, impacting treatment efficacy and safety.

Cite This Study

Ekström-Rydén et al. (2026) studied this question.

synapsesocial.com/papers/69eb0899553a5433e34b383dhttps://doi.org/10.1016/j.esmoop.2026.106068
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 5309: ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, induces tumor localized immune cell activation in preclinical <i>in vivo</i> tumor model2024
  2. 2Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation2024
  3. 3ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation2024 · 19 citations
  4. 4A phase I monotherapy dose escalation study of HFB301001, a novel next generation OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors.2024 · 3 citations
  5. 5Striking the Balance with a PD-L1×4–1BB Bispecific Antibody2024 · 2 citations